IMA901 — Competitive Intelligence Brief

IMA901 (IMA901) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Personalized neoantigen vaccine. Area: Oncology.

phase 3 Personalized neoantigen vaccine Patient-specific tumor neoantigens Oncology Small molecule

Target snapshot

IMA901 (IMA901) — Immatics Biotechnologies GmbH. IMA901 is a personalized neoantigen vaccine that trains the immune system to recognize and attack cancer cells expressing patient-specific tumor mutations.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
IMA901 TARGET	IMA901	Immatics Biotechnologies GmbH	phase 3	Personalized neoantigen vaccine	Patient-specific tumor neoantigens
aMIL	aMIL	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	marketed	Personalized neoantigen vaccine	Patient-specific tumor neoantigens
Begrivac®	Begrivac®	Chiltern Pesquisa Clinica Ltda	phase 3	Therapeutic cancer vaccine	Patient-specific tumor neoantigens
MSB0010718C	MSB0010718C	Istituto Oncologico Veneto IRCCS	phase 3	Therapeutic cancer vaccine	Patient-specific tumor neoantigens
TAK-019	TAK-019	Takeda	phase 3	Therapeutic cancer vaccine	Patient-specific tumor neoantigens
HAPREP®	HAPREP®	National Cancer Center, Korea	phase 3	Therapeutic cancer vaccine	Patient-specific tumor neoantigens
mRNA-1010	mRNA-1010	ModernaTX, Inc.	phase 3	Personalized neoantigen vaccine	Patient-specific tumor neoantigens

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Personalized neoantigen vaccine class)

1. Immatics Biotechnologies GmbH · 2 drugs in this class
2. ModernaTX, Inc. · 1 drug in this class
3. SWOG Cancer Research Network · 1 drug in this class
4. Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · 1 drug in this class